| 479 |
First Line LPA [FLLPA] |
27/04/2022 |
|
| 480 |
Second Line LPA [SLLPA] |
27/04/2022 |
|
| 2044 |
LPA Biosafety |
27/04/2022 |
|
| 2046 |
LPA Quality Assurance |
27/04/2022 |
|
| 2045 |
LPA Reporting, Interpretation of results and evaluation of LPA Assay strips |
27/04/2022 |
|
| 2047 |
LPA Processes |
28/04/2022 |
|
| 2052 |
Contamination control |
28/04/2022 |
|
| 2051 |
Hybridization |
28/04/2022 |
|
| 2050 |
PCR for LPA |
28/04/2022 |
|
| 1427 |
Medication Event Reminder Monitor [MERM] Boxes |
28/04/2022 |
|
| 112 |
Naming Tuberculosis |
03/05/2022 |
|
| 1253 |
Line Probe Assay [LPA] in DR-TB Diagnosis |
03/05/2022 |
|
| 11 |
Microbiology and Pathogenesis of TB |
03/05/2022 |
|
| 13 |
Organizational Structure of NTEP |
03/05/2022 |
|
| 7 |
Tuberculosis |
03/05/2022 |
|
| 9 |
Evolution of TB control programs |
03/05/2022 |
|
| 91 |
National Strategic Plan [NSP] for TB Elimination 2017-25 |
03/05/2022 |
|
| 1720 |
Structure and Function of the CBNAAT Module |
03/05/2022 |
|
| 1595 |
Local Self Government [LSG] |
03/05/2022 |
|
| 2088 |
Information Systems in NTEP |
03/05/2022 |
|
| 2090 |
Zoonotic TB: Mode of transmission |
04/05/2022 |
|
| 2091 |
Zoonotic TB: Signs and symptoms |
04/05/2022 |
|
| 2089 |
Zoonotic TB |
04/05/2022 |
|
| 2098 |
Integration with NTEP and/or other programs |
04/05/2022 |
|
| 2092 |
Zoonotic TB: Testing and diagnosis |
04/05/2022 |
|
| 2093 |
Zoonotic TB: Treatment and management |
04/05/2022 |
|
| 477 |
Line Probe Assay [LPA] |
04/05/2022 |
|
| 2094 |
Zoonotic TB: Prevention |
05/05/2022 |
|
| 135 |
TB Arogya Saathi Application |
05/05/2022 |
|
| 136 |
Enrolling a patient in Nikshay |
05/05/2022 |
|
